A new trading day began on Monday, with Lyra Therapeutics Inc (NASDAQ: LYRA) stock price up 4.01% from the previous day of trading, before settling in for the closing price of $0.10. LYRA’s price has ranged from $0.08 to $5.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 78.20% over the past five years. Meanwhile, its annual earnings per share averaged 42.42%. With a float of $54.86 million, this company’s outstanding shares have now reached $65.52 million.
Let’s look at the performance matrix of the company that is accounted for 30 employees. In terms of profitability, gross margin is -773.53%, operating margin of -6280.83%, and the pretax margin is -6088.4%.
Lyra Therapeutics Inc (LYRA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lyra Therapeutics Inc is 16.73%, while institutional ownership is 37.95%. The most recent insider transaction that took place on Apr 09 ’25, was worth 3,545.
Lyra Therapeutics Inc (LYRA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.95% during the next five years compared to -2.22% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Here are Lyra Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc (NASDAQ: LYRA) saw its 5-day average volume 1.96 million, a positive change from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 30.26%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 14.91%, which indicates a significant decrease from 29.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.05% in the past 14 days, which was higher than the 83.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1680, while its 200-day Moving Average is $0.2285. Nevertheless, the first resistance level for the watch stands at $0.1172 in the near term. At $0.1280, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.1379. If the price goes on to break the first support level at $0.0965, it is likely to go to the next support level at $0.0866. Assuming the price breaks the second support level, the third support level stands at $0.0758.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
With a market capitalization of 7.00 million, the company has a total of 65,881K Shares Outstanding. Currently, annual sales are 1,530 K while annual income is -93,440 K. The company’s previous quarter sales were 210 K while its latest quarter income was -10,980 K.
